

Performance in Initiating (Q3)					
The Research Ethics Committee (REC) reference number	The Integrated Research Application System (IRAS) Number	The name of the trial	The date of receipt of a Valid Research Application	The date of the recruitment of first patient	Where the benchmark has not been achieved for a particular clinical trial, the reason for not doing so
14/LO/1756	140633	OPTcare	19/01/2016	14/03/2016	Yes
14/SC/1345	158326	Prism	29/01/2016	17/02/2016	Yes
13/NE/0339	131556	Got-It	04/02/2016	06/08/2016	No- NHS Provider
14/ES/1004	101577	PRE-EMPT	04/02/2016		No- Sponsor delay
13/EM/0118	101849	Elfin	12/02/2016	04/03/2016	Yes
15/YH/0214	180004	Accuracy total Immunoglobulin Test Device- CDIGE0012201	08/02/2016	23/03/2016	Yes
15/NE/0324	172703	PD STAT	11/02/2016	19/04/2016	Yes
14/SC/1206	142485	ElaTION	19/02/2016	13/04/2016	Yes
14/YH/1315	167170	CoMFFort-Q in CIEDs	29/03/2016	12/04/2016	Yes
15/SC/0019	164489	CORKA	29/03/2016	07/06/2016	Yes
12/WA/0374	98726	HART	06/04/2016	16/05/2016	Yes
15/EE/0446	190666	INS-312	29/03/2016	01/06/2016	Yes
15/NW/0697	183760	Reach	29/03/2016	22/09/2016	No- Sponsor delay
15/NW/0698	183781	REGAIN	29/03/2016	26/09/2016	No- Sponsor delay
11/EE/0347	75112	ECST2	29/03/2016		No- Staff availability Staff availability issues
14/LO/0303	144806	The UK-AIH Cohort	29/03/2016	19/07/2016	Contracting delays
07/MRE08/9	32990	Badbir	29/03/2016	10/05/2016	Yes

Performance in Initiating (Q3) HRA Approval										
The Research Ethics Committee (REC) reference number	The Integrated Research Application System (IRAS) Number	The name of the clinical trial	The date the site was invited	The date the site was selected	The HRA Approval date	The date the site was confirmed by the sponsor	The date the site was confirmed	The date when the site is ready to start	The date of the recruitment of first patient, and	Reasons for delay in recruiting the first patient into a trial.
16/EM/0193	190690	Dalcor	09/06/2016	09/06/2016	14/06/2016	21/06/2016	28/06/2016	09/09/2016	15/09/2016	No- Sponsor Delay
16/EE/0223	201450	Sanofi LPS14584	16/06/2016	16/06/2016	19/08/2016	08/09/2016	13/09/2016	16/09/2016	13/01/2017	No- Sponsor Delay
15/SC/0123	149983	PGRx stroke	02/09/2016	02/09/2016	05/07/2016	15/09/2016	05/09/2016	22/09/2016	22/10/2016	Yes
16/LO/0631	198753	Alcohol	04/07/2016	04/07/2016	20/04/2016	06/01/2017	06/01/2017	09/11/2016		No- Sponsor Delay
15/NW/0545	156861	DexEnceph	27/09/2016	28/09/2016	15/06/2016	09/11/2016	14/11/2016	14/11/2016		No- Rare Disease
16/LO/1272	150869	Aeolus	01/02/2016	11/02/2016	02/12/2016	21/11/2016	24/11/2016	30/11/2016	19/12/2016	No- awaiting HRA Approval
16/LO/1154	186097	IHypE	13/09/2016	15/11/2016	29/09/2016	30/11/2016	28/11/2016	28/11/2016	15/12/2016	Yes
16/NE/0311	211096	AMORE	15/09/2016	01/11/2016	18/10/2016	12/01/2017	12/01/2017	21/12/2016		This study involves 3 different areas Rheumatology, Gastroenterology and Dermatology patients- Sponsor has confirmed activation for Rheumatology. Gastroenterology & Dermatology areas are yet to be confirmed
16/LO/1625	173719	Ariadne	15/09/2016	28/11/2016	28/09/2016	17/01/2017	17/01/2017	09/01/2017	25/01/2017	Yes